Cellectis SA
(XPAR:ALCLS)
€
1.48
-0.02 (-1.33%)
Market Cap: 148.14 Mil
Enterprise Value: -14.65 Mil
PE Ratio: 0
PB Ratio: 1.29
GF Score: 44/100 Cellectis SA at Goldman Sachs Healthcare Conference Transcript
Jun 15, 2023 / 05:00PM GMT
Release Date Price:
€1.91
(-0.16%)
Anoumid Vaziri
Goldman Sachs Group, Inc., Research Division - Research Analyst
Good morning, everyone. I'm Anoumid Vaziri. And I'm joined on stage with Bing Wang, CFO of Cellectis. Bing, thank you for being here with us today.
Bing C. Wang
Cellectis S.A. - CFO
Thank you for inviting me.
Questions & Answers
Anoumid Vaziri
Goldman Sachs Group, Inc., Research Division - Research Analyst
And so to start, Cellectis is a clinical stage biotech company using its TALENs gene editing platform to develop allogeneic cell therapies. Could you provide an overview of your portfolio, both on the partnered and the wholly-owned assets and then discuss how you're differentiated as a company in the cell therapy space?
Bing C. Wang
Cellectis S.A. - CFO
Great. Thank you very much. So I would say we would put our portfolio in 3 buckets. The first is our wholly-owned clinical asset. So we have UCART22 going after ALL. We have UCART123 going after AML. We can go into that in
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot